Gene copy number analysis in malignant pleural mesothelioma using oligonucleotide array CGH

Cytogenetic and Genome Research

Volumn 119, Issue 1-2, 2007, Pages 46-52

  Lindholm, P M ^a   Salmenkivi, K ^a   Vauhkonen, H ^a   Nicholson, A G ^b   Anttila, S ^c   Kinnula, V L ^a   Knuutila, S ^a,d  

^a UNIVERSITY OF HELSINKI   (Finland)

^b ROYAL BROMPTON HOSPITAL   (United Kingdom)

^c FINNISH INSTITUTE OF OCCUPATIONAL HEALTH   (Finland)

^d UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ASBESTOS; DNA;

ARTICLE; CHROMOSOME 13; CHROMOSOME 14; CHROMOSOME 17Q; CHROMOSOME 1P; CHROMOSOME 22; CHROMOSOME 3P; CHROMOSOME 6Q; CHROMOSOME 9P; CHROMOSOME ABERRATION; CIGARETTE SMOKING; CLINICAL ARTICLE; COMPARATIVE GENOMIC HYBRIDIZATION; CYTOGENETICS; ENVIRONMENTAL EXPOSURE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPHOCYTE; MALE; MALIGNANT TRANSFORMATION; MESOTHELIOMA; MESOTHELIUM CELL; PLEURA MESOTHELIOMA; PRIORITY JOURNAL;

GENE DOSAGE; GENOME, HUMAN; HUMANS; MESOTHELIOMA; NUCLEIC ACID HYBRIDIZATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PLEURAL NEOPLASMS;

EID: 37549058023     PISSN: 14248581     EISSN: None     Source Type: Journal    
DOI: 10.1159/000109618     Document Type: Article

References (42)

1. Ascoli V, Scalzo CC, Bruno C, Facciolo F, Lopergolo M, et al: Familial pleural malignant mesothelioma: clustering in three sisters and one cousin. Cancer Lett 130:203-207 (1998).
2. Ascoli V, Aalto Y, Carnovale-Scalzo C, Nardi F, Falzetti D, et al: DNA copy number changes in familial malignant mesothelioma. Cancer Genet Cytogenet 127:80-82 (2001).
3. Balsara BR, Bell DW, Sonoda G, De Rienzo A, du Manoir S, et al: Comparative genomic hybridization and loss of heterozygosity analyses identify a common region of deletion at 15q11.1-15 in human malignant mesothelioma. Cancer Res 59:450-454 (1999).
4. Baudis M, Cleary ML: Progenetix.net: an online repository for molecular cytogenetic aberration data. Bioinformatics 17:1228-1229 (2001).
5. Bjorkqvist AM, Tammilehto L, Anttila S, Mattson K, Knuutila S: Recurrent DNA copy number changes in 1q, 4q, 6q, 9p, 13q, 14q and 22q detected by comparative genomic hybridization in malignant mesothelioma. Br J Cancer 75:523-527 (1997).
6. Bjorkqvist AM, Tammilehto L, Nordling S, Nurminen M, Anttila S, et al: Comparison of DNA copy number changes in malignant mesothelioma, adenocarcinoma and large-cell anaplastic carcinoma of the lung. Br J Cancer 77:260-269 (1998).
7. Bjorkqvist AM, Wolf M, Nordling S, Tammilehto L, Knuuttila A, et al: Deletions at 14q in malignant mesothelioma detected by microsatellite marker analysis. Br J Cancer 81:1111-1115 (1999).
8. Carbone M, Pass HI: Evolving aspects of mesothelioma carcinogenesis: SV40 and genetic predisposition. J Thorac Oncol 1:169-171 (2006).
9. Dogan AU, Baris YI, Dogan M, Emri S, Steele I, et al: Genetic predisposition to fiber carcinogenesis causes a mesothelioma epidemic in Turkey. Cancer Res 66:5063-5068 (2006).
10. El-Rifai W, Larramendy ML, Bjorkqvist A-M, Hemmer S, Knuutila S: Optimization of comparative genomic hybridization using fluorochrome conjugated to dCTP and dUTP nucleotides. Lab Invest 77:699-700 (1997).
11. Flejter WL, Li FP, Antman KH, Testa JR: Recurring loss involving chromosomes 1, 3, and 22 in malignant mesothelioma: possible sites of tumor suppressor genes. Genes Chromosomes Cancer 1:148-154 (1989).
12. Huebner K, Croce CM: FRA3B and other common fragile sites: the weakest links. Nat Rev Cancer 1:214-221 (2001).
13. Huebner K, Garrison PN, Barnes LD, Croce CM: The role of the FHIT/FRA3B locus in cancer. Annu Rev Genet 32:7-31 (1998).
14. Illei PB, Rusch VW, Zakowski MF, Ladanyi M: Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas. Clin Cancer Res 9:2108-2113 (2003).
15. Ishii H, Mimori K, Inoue H, Inageta T, Ishikawa K, et al: Fhit modulates the DNA damage checkpoint response. Cancer Res 66:11287-11292 (2006).
16. Jensen RH, Tiirikainen M, You L, Ginzinger D, He B, et al: Genomic alterations in human mesothelioma including high resolution mapping of common regions of DNA loss in chromosome arm 6q. Anticancer Res 23:2281-2289 (2003).
17. Kivipensas P, Bjorkqvist AM, Karhu R, Pelin K, Linnainmaa K, et al: Gains and losses of DNA sequences in malignant mesothelioma by comparative genomic hybridization. Cancer Genet Cytogenet 89:7-13 (1996).
18. Knuuttila A, Jee KJ, Taskinen E, Wolff H, Knuutila S, et al: Spindle cell tumours of the pleura: a clinical, histological and comparative genomic hybridization analysis of 14 cases. Virchows Arch 448:1-7 (2005).
19. Kohno T, Yokota J: Molecular processes of chromosome 9p21 deletions causing inactivation of the p16 tumor suppressor gene in human cancer: deduction from structural analysis of breakpoints for deletions. DNA Repair 5:1273-1281 (2006).
20. Krismann M, Muller KM, Jaworska M, Johnen G: Molecular cytogenetic differences between histological subtypes of malignant mesotheliomas: DNA cytometry and comparative genomic hybridization of 90 cases. J Pathol 197:363-371 (2002).
21. Kroczynska B, Cutrone R, Bocchetta M, Yang H, Elmishad AG, et al: Crocidolite asbestos and SV40 are cocarcinogens in human mesothelial cells and in causing mesothelioma in hamsters. Proc Natl Acad Sci USA 103:14128-14133 (2006).
22. Lee WC, Balsara B, Liu Z, Jhanwar SC, Testa JR: Loss of heterozygosity analysis defines a critical region in chromosome 1p22 commonly deleted in human malignant mesothelioma. Cancer Res 56:4297-4301 (1996).
23. Lopez-Rios F, Chuai S, Flores R, Shimizu S, Ohno T, et al: Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and P16/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction. Cancer Res 66:2970-2979 (2006).
24. Murthy SS, Testa JR: Asbestos, chromosomal deletions, and tumor suppressor gene alterations in human malignant mesothelioma. J Cell Physiol 180:150-157 (1999).
25. Muscat JE, Wynder VL: Cigarette smoking, asbestos exposure, and malignant mesothelioma. Cancer Res 51:2263-2267 (1991).
26. Musti M, Cavone D, Aalto Y, Scattone A, Serio G, et al: A cluster of familial malignant mesothelioma with del(9p) as the sole chromosomal anomaly. Cancer Genet Cytogenet 138:73-76 (2002).
27. Nymark P, Wikman H, Ruosaari S, Hollmen J, Vanhala E, et al: Identification of specific gene copy number changes in asbestos-related lung cancer. Cancer Res 66:5737-5743 (2006).
28. Papp T, Schipper H, Pemsel H, Bastrop R, Muller KM, et al: Mutational analysis of N-ras, p53, p16INK4a, p14ARF and CDK4 genes in primary human malignant mesotheliomas. Int J Oncol 18:425-433 (2001).
29. Poulikakos PI, Xiao GH, Gallagher R, Jablonski S, Jhanwar SC, et al: Re-expression of the tumor suppressor NF2/merlin inhibits invasiveness in mesothelioma cells and negatively regulates FAK . Oncogene 25: 5960-5968 (2006).
30. Pylkkanen L, Sainio M, Ollikainen T, Mattson K, Nordling S, et al: Concurrent LOH at multiple loci in human malignant mesothelioma with preferential loss of NF2 gene region. Oncol Rep 9:955-959 (2002).
31. Pylkkanen L, Wolff H, Stjernvall T, Knuuttila A, Anttila S, et al: Reduced Fhit protein expression in human malignant mesothelioma. Virchows Arch 444:43-48 (2004).
32. Savola S, Nardi F, Scotlandi K, Picci P, Knuutila K: Microdeletions in 9p21.3 induce false negative results in CDKN2A FISH analysis of Ewing sarcoma. Cytogenet Genome Res 119:21-26 (2007).
33. Schipper H, Papp T, Johnen G, Pemsel H, Bastrop R, et al: Mutational analysis of the nf2 tumour suppressor gene in three subtypes of primary human malignant mesotheliomas. Int J Oncol 22:1009-1017 (2003).
34. Selikoff I, Hammond E, Churg J: Asbestos exposure, smoking, and neoplasia. JAMA 204:106-112 (1968).
35. Spugnini EP, Bosari S, Citro G, Lorenzon I, Cognetti F, et al: Human malignant mesothelioma: molecular mechanisms of pathogenesis and progression. Int J Biochem Biol 38:2000-2004 (2006).
36. Sugarbaker DJ, Flores RM, Jaklitsch MT, Richards WG, Strauss GM, et al: Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 117:54-63; discussion 63-65 (1999).
37. Taguchi T, Jhanwar SC, Siegfried JM, Keller SM, Testa JR: Recurrent deletions of specific chromosomal sites in 1p, 3p, 6q, and 9p in human malignant mesothelioma. Cancer Res 53:4349-4355 (1993).
38. Taniguchi T, Karnan S, Fukui T, Yokoyama T, Tagawa H, et al: Genomic profiling of malignant pleural mesothelioma with array-based comparative genomic hybridization shows frequent non-random chromosomal alteration regions including JUN amplification on 1p32. Cancer Sci 98:438-446 (2007).
39. Tiainen M, Tammilehto L, Rautonen J, Tuomi T, Mattson K, et al: Chromosomal abnormalities and their correlations with asbestos exposure and survival in patients with mesothelioma. Br J Cancer 60:618-626 (1989).
40. Wikman H, Nymark P, Vayrynen A, Jarmalaite S, Kallioniemi A, et al: CDK4 is a probable target gene in a novel amplicon at 12q13.3-q14.1 in lung cancer. Genes Chromosomes Cancer 42:193-199 (2005).
41. Wikman H, Ruosaari S, Nymark P, Sarhadi VK, Saharinen J, et al: Gene expression and copy number profiling suggests the importance of allelic imbalance in 19p in asbestos-associated lung cancer. Oncogene 26:4730-4737 (2007).
42. Xiao GH, Gallagher R, Shetler J, Skele K, Altomare DA, et al: The NF2 tumor suppressor gene product, merlin, inhibits cell proliferation and cell cycle progression by repressing cyclin D1 expression. Mol Cell Biol 25:2384-2394 (2005).